Swiss biotech startup ALP Bio secured €161,000 (CHF 150,000) from Venture Kick. The funding will support the commercial development of its AI-powered platform for identifying immune-related risks earlier in biologic drug development and will fund first pilot projects and early collaborations with pharmaceutical partners.
About ALP Bio
Swiss biotech startup ALP Bio is developing an AI-powered platform that helps drug developers identify immune-related risks earlier in the development process. The platform combines human tonsil-derived immune models with AI-based protein modelling to predict how the immune system is likely to respond to therapeutic antibodies, supporting safer biologic medicines.
Zurich, Switzerland
Read Company ProfileFrequently Asked Questions
What type of funding round did ALP Bio raise?
ALP Bio raised a grant round.
How much did ALP Bio raise in its grant?
ALP Bio raised $161,000 EUR in its grant.
When did ALP Bio raise its grant?
ALP Bio raised its grant on 2026-07-03.
Who invested in ALP Bio's grant?
The investors in ALP Bio's grant are: Venture Kick.
What type of investment was ALP Bio's grant?
ALP Bio's grant was a equity investment.
How will ALP Bio use the funds from its grant?
ALP Bio plans to use the funds for: support the commercial development of its platform, support first pilot projects with pharmaceutical partners, co-finance early collaborations with pharmaceutical partners, validate its technology in real-world settings, facilitate adoption, strengthen its commercial position.